News

VIPC Awards Commonwealth Commercialization Fund Grant to PS Fertility to Advance Fertility Testing

The Virginia Innovation Partnership Corporation (VIPC) today announced that PS-Fertility, Inc. has been awarded a Commonwealth Commercialization Fund (CCF) grant for $75,000. VIPC’s CCF programs have distributed more than $53 million to Virginia-based startups, entrepreneurs, and university-based inventors since 2012 in support of critical early technology testing and market validation efforts. PS Fertility has also previously received funding from VIPC’s Virginia Venture Partners.

 

Each year in the U.S. alone, approximately 7 million couples seek fertility care. Roughly 50% of infertility is due to the male, yet historically the reasons why are largely a mystery and the diagnostic and treatment burdens have fallen disproportionately on the female. PS Fertility, a clinical diagnostic company spun out of the University of Virginia, is changing the way male fertility testing is conducted with their novel discovery that quantifies the levels of fertilization-competent sperm. Equipped with this information, healthcare providers can better advise couples of the likelihood of fertilization and help guide treatment options.

 

“Our patent-pending technology takes fertility testing to a new level beyond just sperm counting and motility measurement. We can assess the ability of a sperm to fertilize an egg, allowing us to uncover meaningful information about male infertility that’s not currently available through conventional testing. This helps provide couples with insight into their personal fertility journey and improve their ability to conceive,” said Dr. Jeffrey Lysiak, Chief Scientific Officer and Co-Founder of PS Fertility. “CCF grant funding is giving us the opportunity to bring our goal of increasing the number of babies born one step closer to reality. We are grateful for VIPC’s partnership.”

 

With CCF support, PS Fertility will complete the transfer of the technology from UVA to the Charlottesville-based company’s commercial lab. Funding will also enable the startup to finalize the at-home collection test kit and begin offering the solution to patients.

 

“The CCF program has long been about fostering innovative and collaborative efforts in the Commonwealth,” said Jeanette Townsend, VIPC’s Director for Private Sector Grants. “Through VIPC’s grant to PS Fertility, we are not only supporting the commercialization activities of a Virginia startup, but also game-changing technology research and development coming out of the University of Virginia. We could not be more excited to be a part of PS Fertility’s story as they transform fertility testing and shift the industry’s 60-year status quo.”

 

Recent News

02/20/2025

Council on State Biotechnology Associations says NIH funds are a critical component of innovation ecosystem

“Today, the US biotech industry employs nearly 2.3 million people across the US and is making positive contributions to economic impact and national security across all 50 states. In fact, for every dollar the National Institutes of Health (NIH) contributes to a successful drug, the private sector invests over $65, underscoring the agency’s unparalleled return

02/11/2025

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions,  announced a strategic partnership with BRAINBox Solutions, a leader in multi-modality diagnostics for traumatic brain injury (TBI). This collaboration seeks to develop the first intranasal therapy for mild traumatic brain injury (mTBI) aka concussion, creating a comprehensive trigger-to-treat

02/11/2025

Children’s National and Compremium partner on pediatric medtech innovation

Children’s National Hospital announced a new collaboration with Swiss medical device company Compremium AG to co-develop and commercialize innovative medical technologies designed specifically for pediatric patients. This first-of-its-kind agreement leverages the expertise of Children’s National in pediatric healthcare innovation and Compremium’s non-invasive platform technology for diagnosing pressure-related conditions, accelerating advancements in pediatric medicine. Diagnosing pressure-related